HC Wainwright raises Nuvectis Pharma price target to $39
HC Wainwright & Co. analyst Joseph Pantginis maintained a Buy rating on Nuvectis Pharma and raised the price target to $39 from $13.
*this image is generated using AI for illustrative purposes only.
HC Wainwright & Co. analyst Joseph Pantginis has maintained a Buy rating on Nuvectis Pharma, citing a positive outlook for the company. The firm significantly raised its price target for the stock, increasing it to $39 from the previous $13.
The revised price target reflects increased confidence in Nuvectis Pharma's potential. The company is listed on NASDAQ under the ticker symbol NVCT.
What specific catalysts or milestones does Nuvectis Pharma need to achieve to justify the new $39 price target?
How might the market react if upcoming clinical trial results or regulatory updates fall short of HC Wainwright's expectations?
Could this price target increase attract institutional investors or lead to a short-term rally in NVCT shares?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
